Quote:

---

in other words, all of cydy's disease-specific patents are as yet unawarded so the uspto 20 year clock is not yet begun?

---

I believe that Cytodyn has specific patents on HIV and Covid (recent) and most likely for a few other indications. Approval of generics is not based on subsequent indication patents but the original molecule patent. FDA exclusivity exists because the length of time it takes for approval could mean the original patent may have expired, giving little reason for the development of new drugs. The individual indication patents would preclude generics from advertising for those indications but like I said it would not preclude off label use.

Which is why after approval we want to get as many trials done as quickly as possible to build up a huge warchest. With massive amounts of money we can buy other pharmaceutical companies with promising drugs big and small.

Now you know why I've been preaching Cytodyn should distribute itself to maximize revenues and why it needs to become a full fledged pharmaceutical company. If you want to survive in a cutthroat business you have to think three moves ahead.